Last $10.52 USD
Change Today -0.08 / -0.75%
Volume 4.0K
ALDX On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 2:31 PM 03/4/15 All times are local (Market data is delayed by at least 15 minutes).

aldeyra therapeutics inc (ALDX) Snapshot

Open
$10.60
Previous Close
$10.60
Day High
$10.81
Day Low
$10.50
52 Week High
01/28/15 - $13.50
52 Week Low
08/4/14 - $3.00
Market Cap
58.5M
Average Volume 10 Days
15.8K
EPS TTM
--
Shares Outstanding
5.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ALDEYRA THERAPEUTICS INC (ALDX)

Related News

No related news articles were found.

aldeyra therapeutics inc (ALDX) Related Businessweek News

No Related Businessweek News Found

aldeyra therapeutics inc (ALDX) Details

Aldeyra Therapeutics, Inc. is a biotechnology company that focuses primarily on the development of products to treat diseases related to free aldehydes. The company develops a family of aldehyde traps, which include new chemical entities that bind to and allow for the disposal of free aldehydes. Its products include NS2, a product candidate to bind and trap free aldehydes. Aldeyra Therapeutics, Inc. was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. The company was founded in 2004 and is based in Lexington, Massachusetts.

6 Employees
Last Reported Date: 11/12/14
Founded in 2004

aldeyra therapeutics inc (ALDX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $70.8K
Chief Operating Officer
Total Annual Compensation: $300.0K
Compensation as of Fiscal Year 2013.

aldeyra therapeutics inc (ALDX) Key Developments

Aldeyra Therapeutics, Inc. Provides Update on NS2 Clinical Program

Aldeyra Therapeutics, Inc. provided an update on its planned clinical trial programs in noninfectious anterior uveitis and Sjögren-Larsson Syndrome, as part of its webcast presentation at the Cowen and Company 35th Annual Healthcare Conference on March 2, 2015. The U.S. Food and Drug Administration (FDA) has notified Aldeyra that, before initiation of Aldeyra's planned Phase II clinical study of NS2 in patients with noninfectious anterior uveitis, the protocol submitted as part of the company's Investigational New Drug Application requires amending. Aldeyra has submitted an amended protocol that the company believes will be acceptable to the FDA. Specifically, in the amended protocol, a minority subset of the most severe uveitis patients are excluded from enrollment, and the frequency of dosing was reduced to treat less severe disease and match the dosing frequency employed in the Phase I study. Consistent with earlier guidance, and subject to FDA review of the modified protocol, the trial is expected to begin enrollment in the first half of 2015, with preliminary data available by the end of the year. The company's Phase II clinical trial of a dermatologic formulation of NS2 to treat ichthyosis and other skin manifestations of Sjögren-Larsson Syndrome is expected to begin enrollment pending final Institutional Review Board (IRB) approval. Consistent with earlier guidance, final data from the trial are expected in the second half of 2015. NS2 is an aldehyde-binding small molecule based on an innovative platform technology focused on trapping free aldehydes, which are toxic and pro-inflammatory mediators of numerous diseases. By decreasing aldehyde load, NS2 may mitigate pathologic inflammation and address other diseases where aldehydes are thought to mediate pathology.

Aldeyra Therapeutics, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-02-2015 04:50 PM

Aldeyra Therapeutics, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-02-2015 04:50 PM. Venue: The Boston Marriott Copley Place, Boston, Massachusetts, United States. Speakers: Todd C. Brady, Chief Executive Officer, President and Director.

Aldeyra Therapeutics, Inc. Submits Investigational New Drug Application to FDA for Clinical Testing of NS2 in Patients with Sjogren-Larsson Syndrome

Aldeyra Therapeutics, Inc. announced that an Investigational New Drug application (IND) to conduct Phase 2 clinical testing of NS2 for the treatment of Sjogren-Larsson Syndrome (SLS) was submitted to the United States Food and Drug Administration (FDA) on December 30, 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALDX:US $10.52 USD -0.08

ALDX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ALDX.
View Industry Companies
 

Industry Analysis

ALDX

Industry Average

Valuation ALDX Industry Range
Price/Earnings 7.5x
Price/Sales -- Not Meaningful
Price/Book 7.1x
Price/Cash Flow 9.0x
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALDEYRA THERAPEUTICS INC, please visit www.aldeyra.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.